International Stem Cell Corporation (ISCO) Commences Enrollment of Phase I Trial of ISC-hpNSC
Before the opening bell, International Stem Cell Corporation (OTCQB: ISCO) took a major step in the development of its human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC) for the treatment of moderate to severe Parkinson’s disease when it announced the commencement of enrollment for its upcoming phase I clinical trial. This announcement followed the Melbourne Health Human Research Ethics Committee’s (HREC) recent decision to grant approval of the phase I clinical trial in patients with moderate to severe Parkinson’s disease. The trial is scheduled to take place at the Royal Melbourne Hospital in Australia. “Enrollment in this trial is an…